- Home
- U vs LEGN Comparison
U vs LEGN Comparison
Compare U & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | U | LEGN |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0B | 5.9B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | U | LEGN |
|---|---|---|
| Price | $45.82 | $21.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 13 |
| Target Price | $39.84 | ★ $69.58 |
| AVG Volume (30 Days) | ★ 8.0M | 2.7M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,803,658,000.00 | $909,045,000.00 |
| Revenue This Year | $3.13 | $68.83 |
| Revenue Next Year | $12.89 | $51.27 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 74.75 |
| 52 Week Low | $15.33 | $21.39 |
| 52 Week High | $52.15 | $45.30 |
Technical Indicators
Market Signals| Indicator | U | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 56.52 | 19.81 |
| Support Level | $43.63 | $26.43 |
| Resistance Level | $52.15 | $28.97 |
| Average True Range (ATR) | 2.25 | 1.26 |
| MACD | -0.30 | -0.36 |
| Stochastic Oscillator | 41.85 | 1.11 |
Price Performance
Historical ComparisonAbout U Unity Software Inc.
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run, and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC, and other Americas, and key revenue is derived from the EMEA region. The products are used in the gaming industry, retail, automotive, architecture, engineering, and construction.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.